Quest Diagnostics Incorporated (NYSE:DGX) Receives Average Recommendation of “Hold” from Analysts

Shares of Quest Diagnostics Incorporated (NYSE:DGXGet Free Report) have been given an average rating of “Hold” by the twelve analysts that are presently covering the stock, MarketBeat reports. Nine investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $146.67.

DGX has been the topic of several recent analyst reports. Truist Financial lifted their price objective on shares of Quest Diagnostics from $145.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, April 24th. SVB Leerink initiated coverage on shares of Quest Diagnostics in a report on Monday, February 26th. They issued a “market perform” rating and a $135.00 price target for the company. Leerink Partnrs reaffirmed a “market perform” rating on shares of Quest Diagnostics in a research note on Monday, February 26th. UBS Group boosted their target price on Quest Diagnostics from $139.00 to $146.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Finally, Barclays raised their price target on Quest Diagnostics from $138.00 to $144.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 25th.

View Our Latest Analysis on DGX

Insiders Place Their Bets

In related news, SVP Karthik Kuppusamy sold 1,760 shares of Quest Diagnostics stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $140.00, for a total transaction of $246,400.00. Following the completion of the transaction, the senior vice president now owns 13,435 shares in the company, valued at $1,880,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.79% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Altshuler Shaham Ltd acquired a new position in Quest Diagnostics in the 4th quarter valued at $26,000. BKM Wealth Management LLC acquired a new position in shares of Quest Diagnostics in the fourth quarter valued at about $29,000. VisionPoint Advisory Group LLC increased its position in Quest Diagnostics by 100.0% during the third quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock worth $27,000 after acquiring an additional 109 shares during the period. Spartan Planning & Wealth Management acquired a new stake in Quest Diagnostics in the 4th quarter worth about $31,000. Finally, Alaska Permanent Fund Corp boosted its holdings in Quest Diagnostics by 79.3% in the 4th quarter. Alaska Permanent Fund Corp now owns 242 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 107 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Trading Down 0.5 %

Shares of NYSE DGX opened at $137.85 on Wednesday. The company’s 50 day simple moving average is $137.29 and its 200 day simple moving average is $133.65. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.97 and a quick ratio of 0.89. Quest Diagnostics has a fifty-two week low of $119.59 and a fifty-two week high of $145.62. The firm has a market capitalization of $15.31 billion, a P/E ratio of 18.55, a P/E/G ratio of 2.99 and a beta of 0.89.

Quest Diagnostics (NYSE:DGXGet Free Report) last posted its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.18. The business had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.29 billion. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The firm’s revenue was up 1.7% on a year-over-year basis. During the same period last year, the company earned $2.04 EPS. On average, analysts predict that Quest Diagnostics will post 8.79 EPS for the current year.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, July 22nd. Investors of record on Monday, July 8th will be issued a dividend of $0.75 per share. The ex-dividend date is Monday, July 8th. This represents a $3.00 dividend on an annualized basis and a yield of 2.18%. Quest Diagnostics’s payout ratio is 40.38%.

Quest Diagnostics Company Profile

(Get Free Report

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Recommended Stories

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with's FREE daily email newsletter.